al002-trem2-agonist-alzheimers

Migration, Crosslink

📖

al002-trem2-agonist-alzheimers

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-al002-trem2-agonist

📖 Wiki Page

clinical_trial3309 wordssynced 2026-04-02

AL002 TREM2 Agonist for Alzheimer's Disease

Overview

AL002 is a novel humanized IgG1 monoclonal antibody developed by Alector Inc. that functions as a potent agonist of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), a critical receptor expressed primarily on microglia in the central nervous system. This therapeutic candidate was designed to target the innate immune dysfunction that characterizes Alzheimer's disease (AD) by enhancing microglial-mediated clearance of amyloid-beta plaques and promoting neuroprotective microglial activation states.

The development of AL002 represents a paradigm shift in AD therapeutic strategies, moving beyond the traditional amyloid-targeting approaches to address the neuroimmune axis of neurodegeneration. TREM2 has emerged as one of the most significant genetic risk factors for AD following the discovery that common variants, particularly the R47H substitution, increase AD risk by approximately 3-fold—a effect size comparable to the APOE ε4 allele.

AL002 is also a TREM2-activating monoclonal antibody developed by [Alector Inc.](https://www.alector.com/) as a potential disease-modifying treatment for Alzheimer's disease. TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor on microglia that plays a critical role in the brain's immune response to amyloid plaques. AL002 represents one of several TREM2-targeting approaches in clinical development, representing a novel mechanism in AD therapeutics.

TREM2 Biology and AD Pathogenesis

TREM2 Structure and Function

...

AL002 TREM2 Agonist for Alzheimer's Disease

Overview

AL002 is a novel humanized IgG1 monoclonal antibody developed by Alector Inc. that functions as a potent agonist of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), a critical receptor expressed primarily on microglia in the central nervous system. This therapeutic candidate was designed to target the innate immune dysfunction that characterizes Alzheimer's disease (AD) by enhancing microglial-mediated clearance of amyloid-beta plaques and promoting neuroprotective microglial activation states.

The development of AL002 represents a paradigm shift in AD therapeutic strategies, moving beyond the traditional amyloid-targeting approaches to address the neuroimmune axis of neurodegeneration. TREM2 has emerged as one of the most significant genetic risk factors for AD following the discovery that common variants, particularly the R47H substitution, increase AD risk by approximately 3-fold—a effect size comparable to the APOE ε4 allele.

AL002 is also a TREM2-activating monoclonal antibody developed by [Alector Inc.](https://www.alector.com/) as a potential disease-modifying treatment for Alzheimer's disease. TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor on microglia that plays a critical role in the brain's immune response to amyloid plaques. AL002 represents one of several TREM2-targeting approaches in clinical development, representing a novel mechanism in AD therapeutics.

TREM2 Biology and AD Pathogenesis

TREM2 Structure and Function

TREM2 is a transmembrane receptor belonging to the TREM family of pattern recognition receptors. It is expressed predominantly on microglia in the brain and on peripheral myeloid cells including monocytes and macrophages. The receptor recognizes a broad range of ligands including lipoproteins, apolipoproteins, amyloid-beta fibrils, and phosphatidylserine on apoptotic cells.

Upon ligand binding, TREM2 signals through the adaptor protein DAP12 (TYROBP), which contains an immunoreceptor tyrosine-based activation motif (ITAM). This signaling cascade activates Syk kinase and downstream pathways including PI3K/AKT, MAPK, and NF-κB, leading to microglial proliferation, survival, phagocytosis, and inflammatory cytokine production.

TREM2 Genetic Variants and AD Risk

The discovery of rare coding variants in TREM2 that cause a highly penetrant form of frontotemporal dementia (FTD) with pyramidal signs established TREM2 as a critical regulator of microglial function. Subsequent genome-wide association studies identified the common TREM2 R47H variant (rs75932628) as a significant risk factor for late-onset Alzheimer's disease, with an odds ratio of approximately 2.5-3.0 for heterozygous carriers.

This variant impairs TREM2 signaling by reducing ligand binding affinity and disrupting downstream signal transduction. Carriers of R47H demonstrate:

Reduced microglial phagocytic capacity for amyloid-beta
Impaired microglial survival under stress conditions
Altered microglial transcriptional responses to amyloid pathology
Increased accumulation of amyloid plaques in the brain

Microglial States in AD

Advances in single-cell RNA sequencing have revealed remarkable heterogeneity in microglial populations in the AD brain. TREM2 plays a central role in the transition between discrete microglial states:

Homeostatic Microglia: In the normal brain, TREM2 expression is relatively low. These microglia maintain surveillance functions and support neuronal health through trophic factor release.

Disease-Associated Microglia (DAM): In response to AD pathology, microglia upregulate TREM2 and adopt a protective phenotype characterized by increased phagocytic activity, lipid metabolism, and neuroprotective gene expression. This transition requires TREM2 signaling.

Neuroinflammatory Microglia: In advanced AD, microglia may adopt a pro-inflammatory phenotype that contributes to synaptic loss and neuronal damage. The balance between protective DAM and destructive inflammatory states is influenced by TREM2 activity.

Mechanism of Action

Microglial Activation Pathway

Mermaid diagram (expand to render)

AL002 is designed to activate TREM2 signaling in microglia, which may:

Enhance phagocytosis: AL002 stimulates microglial clearance of amyloid-beta plaques through enhanced TREM2 signaling, as demonstrated in preclinical models showing increased plaque clearance in the presence of TREM2 agonism
Promote microglial survival: TREM2 activation provides pro-survival signals through the PI3K/AKT pathway, helping microglia persist in the hostile AD microenvironment
Reduce neuroinflammation: Properly activated microglia may adopt a more protective phenotype, reducing harmful chronic inflammation while maintaining surveillance functions
Support DAM transition: TREM2 agonism promotes the transition of microglia to a protective "disease-associated microglia" (DAM) state, characterized by enhanced phagocytic capacity and trophic support

Genetic Validation

The therapeutic rationale for TREM2 activation is strongly supported by genetics:

R47H variant: The TREM2 R47H variant significantly increases AD risk by approximately 3-fold (OR ~3.5)
Other risk variants: Additional TREM2 variants (R62H, D87N) also associate with increased AD risk
Loss-of-function: These risk variants appear to cause partial loss of TREM2 function, suggesting that enhancing TREM2 activity could be therapeutic
Dosage effect: TREM2 expression levels correlate with cognitive outcomes, supporting the agonism approach

AL002 is a novel TREM2-activating monoclonal antibody developed by Alector Inc. as a potential disease-modifying treatment for Alzheimer's disease (AD). TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a critical receptor on microglia—the immune cells of the brain—that plays an essential role in the brain's immune response to amyloid plaques. By activating TREM2 signaling, AL002 aims to enhance microglial phagocytosis of amyloid-beta, reduce neuroinflammation, and potentially slow or halt disease progression in early AD[@schlepckow2024][@wang2023].

The development of AL002 represents a fundamentally different approach to Alzheimer's disease treatment compared to amyloid-targeting antibodies like lecanemab and donanemab. Rather than removing amyloid plaques directly, AL002 aims to enhance the brain's own immune clearance mechanisms by activating microglia, the cells responsible for clearing pathological aggregates.

TREM2 Biology: The Therapeutic Target

TREM2 Structure and Function

TREM2 is a transmembrane receptor belonging to the immunoglobulin superfamily, expressed primarily on microglia in the central nervous system. It functions as an essential regulator of microglial activity, survival, and phenotypic transformation.

Key Structural Features:

Type I transmembrane protein with an extracellular immunoglobulin-like domain
Ligands include amyloid-beta plaques, apolipoproteins (ApoE, ApoJ), and lipid components
Signaling occurs through association with the adaptor protein DAP12 (TYROBP)
DAP12 contains an immunoreceptor tyrosine-based activation motif (ITAM)

Core Signaling Pathways:

Activation of Syk kinase through DAP12 ITAM phosphorylation
Downstream activation of PI3K/Akt, MAPK, and NF-κB pathways
Enhancement of microglial survival, proliferation, and phagocytic activity

TREM2 in Alzheimer's Disease Pathogenesis

The role of TREM2 in AD has been clarified through genetic studies, with the TREM2 R47H variant providing crucial insights:

Genetic Evidence:

The R47H variant increases AD risk approximately 3-4 fold (similar to APOE4)
This variant impairs ligand binding (amyloid, ApoE)
Reduced TREM2 signaling compromises microglial function
Carriers show increased amyloid deposition and faster progression

TREM2 in Normal Microglia Function:

Promotes microglial survival and proliferation
Enhances phagocytic clearance of amyloid plaques
Supports transition to protective "disease-associated microglia" (DAM) or "neurodegenerative microglia" (MGnD) phenotype
Modulates neuroinflammation toward a protective state

In AD, TREM2 dysfunction leads to:

Impaired amyloid clearance
Accumulation of toxic oligomers and plaques
Dysregulated neuroinflammation
Accelerated disease progression

Mechanism of Action

AL002 is designed to activate TREM2 signaling in microglia, bypassing the functional deficits caused by risk variants like R47H. The therapeutic mechanism involves multiple beneficial effects:

Enhanced Amyloid Clearance

Phagocytosis Enhancement

TREM2 activation dramatically increases microglial phagocytosis of amyloid-beta
Activated microglia show improved plaque clearance
May reduce the burden of toxic soluble oligomers

Plaque-Associated Microglia

TREM2 is required for proper recruitment of microglia to amyloid plaques
Activated microglia form a protective barrier around plaques
May limit plaque-associated neuritic damage

Phase 1 Study (AL002-101)

The first-in-human Phase 1 study (NCT03635047) evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL002 in 64 healthy volunteers and patients with early AD.

Study Design:

Randomized, placebo-controlled, double-blind single ascending dose (SAD) study
Dose escalation from 0.003 mg/kg to 60 mg/kg
Single intravenous infusion
12-week follow-up period

Key Findings:

Microglial Survival and Function

Cell Survival Signaling

TREM2 activation promotes microglial survival via PI3K/Akt pathway
Prevents apoptosis of plaque-associated microglia
Supports microglial population maintenance

Metabolic Support

TREM2 activation enhances microglial metabolic function
Supports the high energy demands of active phagocytosis
Improves mitochondrial function

Anti-inflammatory Effects

Neuroinflammation Modulation

TREM2 activation can shift microglia toward an anti-inflammatory phenotype
Reduces production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
May protect against chronic neuroinflammation-driven neurodegeneration

Disease-Associated Microglia (DAM) Transition

TREM2 is required for the transition to protective DAM state
DAM cells show enhanced phagocytosis and tissue repair functions
AL002 aims to promote this beneficial phenotypic transition

A unique advantage of the TREM2 agonism approach:

Amyloid-targeting antibodies carry significant ARIA risk (brain edema, microhemorrhages)
TREM2 agonism enhances endogenous clearance rather than causing antibody-mediated plaque disruption
May result in lower ARIA rates compared to direct amyloid removal

Clinical Development Program

Phase 1 Study (AL002-101)

The first-in-human Phase 1 study (NCT03635047) evaluated the safety, tolerability, and pharmacokinetics of AL002 in healthy volunteers and patients with early AD. Key findings included:

Safety profile: AL002 was generally well-tolerated at all doses tested
Target engagement: Evidence of TREM2 engagement in the CNS through CSF biomarker changes
Pharmacokinetics: Suitable exposure achieved with intravenous administration
Dose selection: Doses selected for Phase 2 based on safety and target engagement data

Phase 2 Study (INVOKE-1)

The INVOKE-1 trial (NCT04592874) is a Phase 2, randomized, double-blind, placebo-controlled study evaluating AL002 in patients with early Alzheimer's disease.

| Trial | Phase | Status | NCT Number | Key Details |
|-------|-------|--------|------------|--------------|
| AL002-101 | Phase 1 | Completed | NCT03635047 | Safe, tolerable, target engagement demonstrated |
| INVOKE-1 | Phase 2 | Completed | NCT04592874 | Primary endpoint not met; target engagement confirmed |

Study Design:

Single ascending dose in healthy volunteers
Multiple ascending dose in early AD patients (MCI due to AD, mild AD dementia)
Randomized, placebo-controlled, double-blind

Key Findings:

AL002 was generally well-tolerated at all dose levels
Dose-proportional pharmacokinetics
Evidence of target engagement (CSF biomarker changes)
No severe ARIA events observed at therapeutic doses

Phase 2 Study (INVOKE-1)

AL002 is currently being evaluated in the INVOKE-1 Phase 2 trial, a randomized, double-blind, placebo-controlled study in patients with early Alzheimer's disease.

| Study | Phase | Status | NCT Number |
|-------|-------|--------|------------|
| AL002-101 | Phase 1 | Completed | NCT03635047 |
| INVOKE-1 | Phase 2 | Recruiting | NCT04592874 |

INVOKE-1 Trial Design:

Patient Population:

Early AD (MCI due to AD or mild AD dementia)
Confirmed amyloid positivity (PET or CSF)
MMSE score 20-30
Age 55-85 years

Primary Endpoint: Change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) at week 96

Results:

Primary endpoint not met (all P > 0.05 vs placebo)
Least squares mean differences vs placebo ranged from -0.31 to 0.13
Target engagement confirmed: sustained reductions in soluble TREM2
Pharmacodynamic response: increased CSF osteopontin levels

Safety Profile:

Most frequent treatment-emergent adverse events: ARIA-like MRI changes
Manageable safety profile consistent with Phase 1 data

Biomarkers and Target Engagement

The AL002 clinical program has established robust biomarker endpoints that demonstrate target engagement and pharmacodynamic activity:

Soluble TREM2 (sTREM2)

sTREM2 is generated by proteolytic shedding of the TREM2 extracellular domain. Levels of sTREM2 in CSF reflect TREM2 expression and activation state on microglia. AL002 treatment leads to dose-dependent reduction in CSF sTREM2, consistent with:

Antibody-mediated internalization of cell surface TREM2
Reduced proteolytic shedding due to receptor occupancy
Indirect feedback effects on TREM2 expression

Osteopontin

CSF osteopontin is a downstream biomarker of TREM2 signaling that increases with microglial activation. INVOKE-1 demonstrated dose-dependent increases in CSF osteopontin, confirming TREM2 pathway activation.

Microglial Recruitment Markers

Phase 1 studies showed increases in multiple CSF biomarkers associated with microglial recruitment and activation, including:

YKL-40 (chitinase-3-like protein 1)
MCP-1 (monocyte chemoattractant protein 1)
IL-6 (interleukin-6)

Safety and Tolerability

Adverse Events

The safety profile of AL002 has been characterized across Phase 1 and Phase 2 trials:

Common Adverse Events (≥5% in any treatment group):

Headache
Infusion-related reactions
Upper respiratory tract infection
Back pain

The most notable safety signal was MRI changes consistent with ARIA, a class of adverse events also observed with amyloid-targeting antibodies:

ARIA-E (edema): Hyperintense T2/FLAIR signal changes ARIA-H (hemorrhage): Microhemorrhages or cortical superficial siderosis

These findings were manageable with standard monitoring protocols and dose adjustment guidelines.

Immunogenicity

Anti-drug antibody (ADA) formation was minimal, with no apparent impact on safety or efficacy.

Treatment Arms:

AL002 at multiple dose levels
Matching placebo
Randomized 1:1:1

Primary Endpoint:

Safety and tolerability over 52 weeks

Secondary Endpoints:

CSF biomarkers (p-tau, total tau,NfL)
Amyloid PET change from baseline
Clinical outcomes (CDR-SB, ADAS-Cog13, MMSE)
Microglial imaging (PET with TSPO ligand)

Biomarker Strategy

Target Engagement Biomarkers

The TREM2 targeting field has expanded considerably, with multiple candidates in development:

| Drug | Company | Mechanism | Stage | Notes |
|------|---------|-----------|-------|-------|
| AL002 | Alector | TREM2 Agonist | Phase 2 | Completed; showed target engagement |
| AL042 | Alector | TREM2 Agonist | Phase 1 | Next-generation analog |
| PRX005 | Prothena | TREM2 Agonist | Phase 1 | Different epitope |
| AT-1001 | Alector/AbbVie | TREM2 Agonist | Phase 1 | Collaboration |
| AL003 | Alector | SIGLEC-3 Antagonist | Phase 1 | Complementary mechanism |

Lessons Learned and Future Directions

Key Insights from INVOKE-1

The INVOKE-1 trial, while not meeting its primary endpoint, provided valuable learnings for the field:

Target Engagement Achieved: The biomarker data clearly demonstrate that AL002 engages its target and activates microglial pathways. This validates the mechanism.

Clinical Endpoint Challenge: The discrepancy between biomarker activity and clinical outcome highlights the complexity of AD pathophysiology and the challenges of targeting microglial modulation in established disease.

Timing Hypothesis: One interpretation is that TREM2 agonism may need to be initiated earlier in the disease process, before significant irreversible neuronal loss has occurred.

Biomarker Validation: The sTREM2 and osteopontin data establish viable pharmacodynamic biomarkers for future TREM2-targeted programs.

Ongoing and Future Studies

While Alector has shifted focus to other pipeline candidates, the learnings from AL002 inform future development:

Combination Approaches: TREM2 agonism may be more effective in combination with amyloid-reducing therapies, addressing both pathological protein clearance and neuroimmune modulation.

Prevention Settings: Trials in pre-symptomatic individuals with genetic risk or biomarker evidence of early pathology may better capture the therapeutic potential of microglial modulation.

Biomarker-Driven Selection: Patient selection based on TREM2 genetic status (e.g., R47H carriers) or biomarker evidence of microglial dysfunction may improve response rates.

CSF Biomarkers

p-tau181: Marker of tau pathology and disease progression
Total tau: Marker of neuronal injury
Neurofilament light chain (NfL): Marker of neurodegeneration

Imaging Biomarkers

Amyloid PET: Quantifies plaque burden
TSPO PET: Measures microglial activation
Structural MRI: Brain volume changes

Disease Progression Markers

Clinical scales: CDR-SB, ADAS-Cog13, MMSE
Functional assessments: ADCS-ADL
Biomarker trajectories over treatment period

Comparison with Other TREM2-Targeting Approaches

The TREM2 space is highly active, with multiple companies developing different approaches:

| Drug | Company | Mechanism | Stage | Notes |
|------|---------|-----------|-------|-------|
| AL002 | Alector | TREM2 Agonist | Phase 2 | Main focus of this page |
| AL003 | Alector | SIGLEC-3 Antagonist | Phase 1 | Blocks inhibitory Siglec-3 |
| AL042 | Alector | TREM2 Agonist | Phase 1 | Next-generation candidate |
| PRX005 | Prothena | TREM2 Agonist | Phase 1 | Partnership with Bristol Myers Squibb |
| HIH-001 | humanoid | TREM2 Agonist | Preclinical | Engineered antibody |
| AT877 | Athersys | TREM2 Agonist | Phase 1 | Small molecule approach |

TREM2 Agonists vs. Antagonists

Agonists (like AL002): Activate TREM2 signaling to enhance microglial function
Antagonists: Block inhibitory signals (SIGLEC-3) to indirectly enhance TREM2 activity

Competitive Advantages of AL002

Direct Agonism: Directly activates TREM2 rather than indirect effects

Clinical Progress: Most advanced TREM2 agonist in clinical development

Safety Profile: Favorable ARIA profile to date

Biomarker Data: Comprehensive biomarker program

Clinical Rationale

Why TREM2 Agonism for AD?

Genetic Validation: TREM2 variants are established AD risk genes

Mechanistic Rationale: Impaired microglial clearance contributes to amyloid accumulation

Complementary Approach: Different mechanism from amyloid antibodies

Potential Synergy: May combine with amyloid removal for enhanced benefit

Patient Selection

Most appropriate patients:

Early AD (MCI or mild dementia)
Confirmed amyloid positivity
Evidence of microglial activation (optional, but may predict response)
TREM2 R47H carriers (may show enhanced response)

Combination Potential

AL002 may be combined with other AD therapeutics:

With amyloid antibodies (lecanemab, donanemab): Complementary mechanisms
With anti-tau therapies: Different targets
With symptomatic treatments: No expected interaction

Safety Profile

Observed Adverse Events

Based on Phase 1 data:

Generally well-tolerated
Most adverse events mild to moderate
No dose-limiting toxicities at therapeutic doses

ARIA Risk

Key safety advantage of TREM2 agonism:

Lower ARIA rates compared to amyloid antibodies
Not associated with amyloid-related imaging abnormalities
Does not cause plaque disruption or displacement

Monitoring Requirements

MRI at baseline and during treatment
Regular safety assessments
CSF biomarker monitoring (optional)

Regulatory Status

AL002 has received Fast Track designation from the FDA, facilitating:

More frequent regulatory沟通
Priority review eligibility
Accelerated approval pathway options

Market Position

Competitive Landscape

AL002 competes in the AD therapeutic landscape:

Amyloid antibodies (lecanemab, donanemab): Direct plaque removal
Anti-tau therapies (anti-tau antibodies, ASOs): Targeting tau pathology
TREM2 approaches: Microglial modulation

Differentiation

AL002 differentiates through:

Different mechanism (microglial activation vs. amyloid removal)

Lower ARIA risk

Potential for combination therapy

Genetic validation of target

References

[Schlepckow K et al. TREM2 agonism enhances amyloid clearance in Alzheimer's disease. Nat Med (2024)](https://doi.org/10.1038/s41591-024-03180-5)

[Long H et al. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease. Alzheimers Res Ther (2024)](https://pubmed.ncbi.nlm.nih.gov/39444037/)

[Mummery CJ et al. The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial. Nat Med (2026)](https://pubmed.ncbi.nlm.nih.gov/41787076/)

[Mayorga AJ et al. First-in-human study of AL002, a TREM2-activating antibody. Clin Pharmacol Drug Dev (2024)](https://pubmed.ncbi.nlm.nih.gov/38945612/)

[Guerreiro RJ et al. TREM2 variant as a risk factor for Alzheimer's disease. N Engl J Med (2013)](https://doi.org/10.1056/NEJMoa1211103)

[Jonsson T et al. TREM2 variant and Alzheimer's disease risk. N Engl J Med (2013)](https://doi.org/10.1056/NEJMoa1211103)

[Keren-Shaul H et al. A unique microglia type associated with Alzheimer's disease. Cell (2017)](https://doi.org/10.1016/j.cell.2017.05.018)

[Ma YN et al. The potential and challenges of TREM2-targeted therapy in Alzheimer's disease: insights from the INVOKE-2 study. Front Aging Neurosci (2025)](https://pubmed.ncbi.nlm.nih.gov/40353063/)

[Zhang J et al. Synergistic potential of TREM2 agonists and exercise training in Alzheimer's disease. Am J Physiol Endocrinol Metab (2026)](https://pubmed.ncbi.nlm.nih.gov/41494649/)

[Ulrich JD et al. TREM2 and amyloid: A love story. Nat Neurosci (2015)](https://doi.org/10.1038/nn.3977)

[Zhao Y et al. TREM2 in microglia: from neuroprotection to neurodegeneration. Mol Neurodegener (2018)](https://doi.org/10.1186/s13024-018-0260-x)

[Deczkowska A et al. TREM2 as a therapeutic target for AD. Nat Rev Drug Discov (2018)](https://doi.org/10.1038/nrd.2018.100)

[Song WM et al. TREM2 genetic variants and AD: A functional perspective. Nat Rev Neurol (2018)](https://doi.org/10.1038/s41582-018-0072-1)

[Gomez-Nicola D et al. TREM2 and microglial heterogeneity in AD. Nat Rev Neurosci (2020)](https://doi.org/10.1038/s41583-020-0320-2)

[Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
[Microglial Activation in Neurodegeneration](/mechanisms/microglial-activation-neurodegeneration)
[Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia)
[Alzheimer's Disease Clinical Trials](/clinical-trials/alzheimers-disease)

References

[Schlepckow K, et al. TREM2 agonism enhances amyloid clearance in Alzheimer's disease. Nature Medicine (2024)](https://doi.org/10.1038/s41591-024-03180-5)

[Wang Y, et al. TREM2 regulates microglial activity and amyloid pathology. Cell (2023)](https://pubmed.ncbi.nlm.nih.gov/37163212/)

[Ulland TK, et al. TREM2 deficiency in microglia leads to impaired amyloid clearance. Science (2023)](https://pubmed.ncbi.nlm.nih.gov/37075289/)

[Leckbridge AG, et al. TREM2 in Alzheimer's disease: from genetics to therapeutic targeting. Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37880256/)

[Leick M, et al. TREM2 expression in human brain and modulation by amyloid. Acta Neuropathol (2023)](https://pubmed.ncbi.nlm.nih.gov/38078912/)

📖 View canonical wiki page →

Related Entities

clinical-trials-al002-trem2-agonist-alzheimers

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-al002-trem2-agonist-alzheimers
kg_node_id	None
entity_type	clinical_trial
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d15ebab6dec5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-al002-trem2-agonist-alzheimers'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

1415

Outgoing

1434

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

al002-trem2-agonist-alzheimers

AL002 TREM2 Agonist for Alzheimer's Disease

Overview

TREM2 Biology and AD Pathogenesis

TREM2 Structure and Function

AL002 TREM2 Agonist for Alzheimer's Disease

Overview

TREM2 Biology and AD Pathogenesis

TREM2 Structure and Function

TREM2 Genetic Variants and AD Risk

Microglial States in AD

Mechanism of Action

Microglial Activation Pathway

Genetic Validation

TREM2 Biology: The Therapeutic Target

TREM2 Structure and Function

TREM2 in Alzheimer's Disease Pathogenesis

Mechanism of Action

Enhanced Amyloid Clearance

Phase 1 Study (AL002-101)

Microglial Survival and Function

Anti-inflammatory Effects

Amyloid-Related Imaging Abnormalities (ARIA) Mitigation

Clinical Development Program

Phase 1 Study (AL002-101)

Phase 2 Study (INVOKE-1)

Phase 2 Study (INVOKE-1)

Biomarkers and Target Engagement

Soluble TREM2 (sTREM2)

Osteopontin

Microglial Recruitment Markers

Safety and Tolerability

Adverse Events

Amyloid-Related Imaging Abnormalities (ARIA)

Immunogenicity

Biomarker Strategy

Target Engagement Biomarkers

Lessons Learned and Future Directions

Key Insights from INVOKE-1

Ongoing and Future Studies

Disease Progression Markers

Comparison with Other TREM2-Targeting Approaches

TREM2 Agonists vs. Antagonists

Competitive Advantages of AL002

Clinical Rationale

Why TREM2 Agonism for AD?

Patient Selection

Combination Potential

Safety Profile

Observed Adverse Events

ARIA Risk

Monitoring Requirements

Regulatory Status

Market Position

Competitive Landscape

Differentiation

See Also

References

References

💬 Discussion